Rapid virologic response in chronic hepatitis C genotype 1: Evaluation of pretreatment factors in patients

Turken M., Kose Ş., Ergun N. C., Tatar B.

ARAB JOURNAL OF GASTROENTEROLOGY, cilt.21, sa.4, ss.278-281, 2020 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.ajg.2020.08.005
  • Dergi Adı: ARAB JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.278-281
  • Anahtar Kelimeler: Hepatitis C virus, Treatment, Response, PEGYLATED INTERFERON, VIRUS, EFFICACY
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Background and study aims: Rapid virologic response (RVR) is defined as undetectable hepatitis C virus (HCV) RNA in serum after 4 weeks of treatment for chronic hepatitis C (CHC). Paritaprevir/ritonavir/ombi tasvir (PRO) and/or dasabuvir (D), with or without ribavirin [PRO (D) ribavirin], which are direct-acting antivirals (DAAs), is the currently approved treatment regimen for CHC genotype 1; this regimen can also be used in patients with end-stage renal failure (ESRF). In this study, we aimed to evaluate the effect of pretreatment factors on RVR in patients treated with PRO (D) +/- ribavirin.